688606 logo

Hangzhou Alltest Biotech XSSC:688606 Stock Report

Last Price

CN¥75.29

Market Cap

CN¥5.8b

7D

-4.7%

1Y

21.5%

Updated

17 Mar, 2025

Data

Company Financials

Hangzhou Alltest Biotech Co., Ltd.

XSSC:688606 Stock Report

Market Cap: CN¥5.8b

688606 Stock Overview

Engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. More details

688606 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance4/6
Financial Health5/6
Dividends2/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Hangzhou Alltest Biotech Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Hangzhou Alltest Biotech
Historical stock prices
Current Share PriceCN¥75.29
52 Week HighCN¥84.72
52 Week LowCN¥45.17
Beta0.45
1 Month Change5.60%
3 Month Change13.97%
1 Year Change21.53%
3 Year Changen/a
5 Year Changen/a
Change since IPO6.89%

Recent News & Updates

Recent updates

Shareholder Returns

688606CN Medical EquipmentCN Market
7D-4.7%1.1%1.5%
1Y21.5%-6.5%13.9%

Return vs Industry: 688606 exceeded the CN Medical Equipment industry which returned -6.5% over the past year.

Return vs Market: 688606 exceeded the CN Market which returned 13.9% over the past year.

Price Volatility

Is 688606's price volatile compared to industry and market?
688606 volatility
688606 Average Weekly Movement5.7%
Medical Equipment Industry Average Movement5.0%
Market Average Movement6.1%
10% most volatile stocks in CN Market10.3%
10% least volatile stocks in CN Market3.5%

Stable Share Price: 688606 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 688606's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009987Fei Gaowww.alltests.com.cn

Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; fluorescence immunoassay tests and analyzers; urine analysis solutions, biochemistry reagents, VTM, blood glucose monitoring systems, and HB hemoglobin test meters.

Hangzhou Alltest Biotech Co., Ltd. Fundamentals Summary

How do Hangzhou Alltest Biotech's earnings and revenue compare to its market cap?
688606 fundamental statistics
Market capCN¥5.84b
Earnings (TTM)CN¥303.69m
Revenue (TTM)CN¥869.79m

19.2x

P/E Ratio

6.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688606 income statement (TTM)
RevenueCN¥869.79m
Cost of RevenueCN¥0
Gross ProfitCN¥869.79m
Other ExpensesCN¥566.10m
EarningsCN¥303.69m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Apr 29, 2025

Earnings per share (EPS)3.92
Gross Margin100.00%
Net Profit Margin34.92%
Debt/Equity Ratio0.2%

How did 688606 perform over the long term?

See historical performance and comparison

Dividends

2.0%

Current Dividend Yield

86%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/17 21:41
End of Day Share Price 2025/03/17 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hangzhou Alltest Biotech Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.